Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Molecular basis of cholinergic changes in autism spectrum disorders and relevance for treatment interventions

Title: Molecular basis of cholinergic changes in autism spectrum disorders and relevance for treatment interventions
Authors: Mukaetova-Ladinska EB; Perry EK
Source: The Molecular Basis of Autism, 1 January 2015
Publisher Information: Springer New York
Publication Year: 2015
Collection: Newcastle University Library ePrints Service
Description: © Springer Science+Business Media New York 2015. The causes of autism are heterogeneous and still largely unknown. Cholinergic abnormalities are reported in molecular pathological studies conducted on brain tissues from adults with autism and may explain the numerous cognitive and behavioural changes seen in the autism spectrum disorders (ASD), including impairment in various cognitive domains, memory and attention. Currently available treatments for the behavioural problems frequently reported in children and adults with ASD are largely for symptomatic relief of irritability, hyperactivity and repetitive stereotyped behaviour. In this review we address current knowledge about the cholinergic changes in ASD and how these are relevant in clinical setting. In particular, we review the prospect of the use of cholinesterase inhibitors and other cholinomimetics (chemicals that can act by either directly stimulating the nicotinic or muscarinic receptors, or promote acetylcholine release) in ASD for treatment of both cognitive and behavioural changes, based on their benefits in neurodegenerative (e.g. Alzheimer’s disease and Lewy Body Spectrum Diseases) and neurodevelopmental disorders (e.g. schizophrenia and Down syndrome). As a result, we provide an overview of the current use of cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and cholinomimetics (e.g. nicotine) in the treatment of cognitive and behavioral symptoms in ASD, and discuss developments of novel cholinergic drug interventions that can safely target core disease mechanisms as early as possible.
Document Type: book part
Language: unknown
Relation: https://eprints.ncl.ac.uk/234988
Availability: https://eprints.ncl.ac.uk/234988
Accession Number: edsbas.586B3A57
Database: BASE